A Study of Amivantamab and Capmatinib Combination Therapy in Unresectable Metastatic Non-small Cell Lung Cancer
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- Registration Number
- NCT05488314
- Lead Sponsor
- Janssen Research & Development, LLC
- Brief Summary
The purpose of this study is to identify the recommended Phase 2 combination dose (RP2CD\[s\]) of the amivantamab and capmatinib combination therapy in participants with non-small cell lung cancer (NSCLC) in Phase 1 (combination dose selection), and to evaluate the antitumor effect of the amivantamab and capmatinib combination therapy in mesenchymal-epithelial transition (MET) exon 14 skipping mutation and MET amplified NSCLC, when administered at the selected RP2CD(s) in Phase 2 (expansion).
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ACTIVE_NOT_RECRUITING
- Sex
- All
- Target Recruitment
- 57
- Previously diagnosed with histologically or cytologically confirmed unresectable Stage IV (metastatic) non-small cell lung cancer (NSCLC) (any histology)
- May have: definitively, locally treated brain metastases that are clinically stable and asymptomatic for greater than (>) 2 weeks and who are off or receiving low-dose corticosteroid treatment (less than or equal to [<=]10 milligrams (mg) prednisone or equivalent) for at least 2 weeks prior to start of study treatment
- May have a prior malignancy (other than the disease under study) the natural history or treatment of which is unlikely to interfere with any study endpoints of safety or the efficacy of the study treatment(s)
- Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
- A participant of childbearing potential must have a negative serum pregnancy test at screening and within 72 hours of the first dose of study treatment and must agree to further serum or urine pregnancy tests during the study
- Medical history of (non-infectious) interstitial lung disease (ILD)/pneumonitis, or has current ILD/pneumonitis, or where suspected ILD/pneumonitis cannot be ruled out by imaging at screening
- Participant has impairment of the gastrointestinal function that could affect absorption of capmatinib or is unable or unwilling to swallow tablets
- Participant has symptomatic central nervous system (CNS) metastases which are neurologically unstable or have required increasing doses of steroids >10 mg prednisone or equivalent within the 2 weeks prior to study entry to manage CNS symptoms
- Participant has uncontrolled tumor-related pain: Symptomatic lesions amenable to palliative radiotherapy (example, bone metastases, or metastases causing nerve impingement) should be treated more than 7 days prior to the administration of the first study treatment
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SEQUENTIAL
- Arm && Interventions
Group Intervention Description Phase 2 (Dose Expansion) Amivantamab Participants with mesenchymal-epithelial transition (MET) exon 14 skipping mutation who are treatment naïve (Cohort 1A), who have received prior therapy (Cohort 1B), or participants with MET amplification who have received prior therapy (Cohort 1C) will receive capmatinib in combination with amivantamab at the RP2CD determined by the SET in Phase 1. Phase 1 (Combination Dose Selection) Capmatinib Participants will receive capmatinib 400 milligrams (mg) orally twice daily from Cycle 1 Day 1, in combination with amivantamab 700 mg intravenous (IV) infusion (for body weight less than 80 kilograms \[kg\]) or 1050 mg IV infusion (for body weight greater than or equal to 80 kg) once weekly from Cycle 1 Day 1 for 4 weeks and then every 2 weeks from Week 5 (Cycle 2; each cycle of 28 days). Doses will be escalated or de-escalated based on the dose limiting toxicities (DLTs) and the recommended Phase 2 combination dose (RP2CD) will be determined by the study evaluation team (SET). Phase 1 (Combination Dose Selection) Amivantamab Participants will receive capmatinib 400 milligrams (mg) orally twice daily from Cycle 1 Day 1, in combination with amivantamab 700 mg intravenous (IV) infusion (for body weight less than 80 kilograms \[kg\]) or 1050 mg IV infusion (for body weight greater than or equal to 80 kg) once weekly from Cycle 1 Day 1 for 4 weeks and then every 2 weeks from Week 5 (Cycle 2; each cycle of 28 days). Doses will be escalated or de-escalated based on the dose limiting toxicities (DLTs) and the recommended Phase 2 combination dose (RP2CD) will be determined by the study evaluation team (SET). Phase 2 (Dose Expansion) Capmatinib Participants with mesenchymal-epithelial transition (MET) exon 14 skipping mutation who are treatment naïve (Cohort 1A), who have received prior therapy (Cohort 1B), or participants with MET amplification who have received prior therapy (Cohort 1C) will receive capmatinib in combination with amivantamab at the RP2CD determined by the SET in Phase 1.
- Primary Outcome Measures
Name Time Method Phase 1: Number of Participants with Dose Limiting Toxicities (DLTs) Cycle 1 (Day 1 through Day 28) The DLTs are specific adverse events and are defined as any of the following: high grade non-hematologic toxicity, hematologic toxicity, pulmonary toxicity, liver enzyme elevation, or treatment delay greater than (\>) 28 days due to unresolved toxicity.
Phase 1: Number of Participants with Adverse events (AEs) by Severity Up to 2 years 1 month An AE is any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non-investigational) product. An adverse event does not necessarily have a causal relationship with the intervention. Severity will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5.0. Severity scale ranges from Grade 1 (Mild) to Grade 5 (Death). Grade 1= Mild, Grade 2= Moderate, Grade 3= Severe, Grade 4= Life-threatening and Grade 5= Death related to adverse event.
Phase 2: Objective Response Rate Up to 2 years 1 month ORR is defined as the percentage of participants who achieve either a confirmed partial response (PR) or complete response (CR), using Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.
- Secondary Outcome Measures
Name Time Method Phase 2: Disease Control Rate (DCR) Up to 2 years 1 month DCR is defined as the percentage of participants who achieve a PR, CR, or stable disease using RECIST version 1.1.
Phase 2: Time to Subsequent Therapy (TTST) Up to 2 years 1 month TTST is defined as the time from the date of administration of the first study treatment to the start date of the subsequent anticancer therapy following study treatment discontinuation, or death, whichever comes first.
Phase 2 (Cohort 1A): Change from Baseline in Health-related Quality of Life in (HRQoL) as Assessed by European Organization of Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC-QLQ-C30) Scale Score Baseline up to 2 years 1 month EORTC-QLQ-C30 is a self-administered, 30-item questionnaire developed to assess the HRQoL of cancer participants.
Phase 2 (Cohort 1A): HRQoL as Assessed by Patient-reported Outcomes Measurement Information System Short Form Version 2.0 - Physical Function 8c (PROMIS PF 8c) Scale Score Up to 2 years 1 month PROMIS PF 8c is an 8-item fixed length short form derived from the PROMIS Physical Function item bank. It assesses activities of daily living, mobility, and global impact of physical functioning.
Phase 1: Number of Participants with AEs by Severity Up to 2 years 1 month An AE is any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non-investigational) product. An adverse event does not necessarily have a causal relationship with the intervention. Severity will be graded according to the NCI-CTCAE version 5.0. Severity scale ranges from Grade 1 (Mild) to Grade 5 (Death). Grade 1= Mild, Grade 2= Moderate, Grade 3= Severe, Grade 4= Life-threatening and Grade 5= Death related to adverse event.
Phase 1: Number of Participants with Abnormalities in Clinical Laboratory Parameters Up to 2 years 1 month Number of participants with abnormalities in clinical laboratory parameters (serum chemistry, hematology, coagulation, serology, and urinalysis) will be reported.
Phase 2: Duration of Response (DoR) Up to 2 years 1 month DoR is defined as the time from the date of first documented response (PR or CR) until the date of documented progression or death from any case, whichever comes first, for participants who have PR or CR.
Phase 2: Progression Free Survival (PFS) Up to 2 years 1 month PFS is defined as the time from first dose date until the date of disease progression or death, whichever comes first, based on investigator assessment using RECIST version 1.1
Phase 2: Overall Survival (OS) Up to 2 years 1 month OS is defined as the time from the date of administration of the first study treatment until the date of death due to any cause.
Phase 2 (Cohort 1A): HRQoL as Assessed by Non-Small Cell Lung Cancer - Symptom Assessment Questionnaire (NSCLC-SAQ) Scale Score Up to 2 years 1 month NSCLC-SAQ assesses patient-reported symptom severity associated with NSCLC.
Phase 2 (Cohort 1A): HRQoL as Assessed by EuroQol 5-Dimension 5-Level (EQ-5D-5L) Scale Score Up to 2 years 1 month EQ-5D-5L is a self-administered, standardized measure of health status.
Trial Locations
- Locations (77)
Fundacao Antonio Prudente A C Camargo Cancer Center
🇧🇷Sao Paulo, Brazil
Shengjing Hospital Of China Medical University
🇨🇳Shenyang, China
PERSONAL Oncologia de Precisao e Personalizada
🇧🇷Belo Horizonte, Brazil
UPCO Unidade de Pesquisa Clinica em Oncologia
🇧🇷Pelotas, Brazil
Uniao Brasileira de Educacao e Assistencia Hospital Sao Lucas da PUCRS
🇧🇷Porto Alegre, Brazil
Shizuoka Cancer Center
🇯🇵Sunto Gun, Japan
The Oncology Institute of Hope and Innovation
🇺🇸Cerritos, California, United States
Montefiore Einstein Center for Cancer Care
🇺🇸Bronx, New York, United States
Virginia Cancer Specialists
🇺🇸Fairfax, Virginia, United States
Oncoclinicas Rio de Janeiro S A
🇧🇷Rio de Janeiro, Brazil
Beijing Cancer Hospital
🇨🇳Beijing, China
Sir Run Run Shaw Hospital Zhejiang University School of Medicine
🇨🇳Hangzhou, China
The First Affiliated Hospital of Xian Jiaotong University
🇨🇳Xi'An, China
Institute Coeur Poumon
🇫🇷Lille, France
CHU de la Timone
🇫🇷Marseille, France
Sociedade Beneficente de Senhoras Hospital Sirio Libanes
🇧🇷São Paulo, Brazil
The Ottawa Hospital Research Institute
🇨🇦Ottawa, Ontario, Canada
Sichuan Cancer Hospital
🇨🇳Chengdu, China
University of Alabama at Birmingham, Comprehensive Cancer Center
🇺🇸Birmingham, Alabama, United States
UCLA
🇺🇸Los Angeles, California, United States
CIONC Centro Integrado de Oncologia de Curitiba
🇧🇷Curitiba, Brazil
Instituto D Or de Pesquisa e Ensino IDOR
🇧🇷Rio de Janeiro, Brazil
Princess Margaret Cancer Centre University Health Network
🇨🇦Toronto, Ontario, Canada
The First Affiliated Hospital Sun Yat sen University
🇨🇳Guangzhou, China
Second Affiliated Hospital, School of Medicine, Zhejiang University
🇨🇳Hangzhou, China
Fudan University Shanghai Cancer Center
🇨🇳Shanghai, China
West China Hospital Sichuan University
🇨🇳Chengdu, China
Chongqing University Cancer Hospital
🇨🇳Chongqing, China
Huizhou Municipal Central Hospital
🇨🇳Huizhou, China
Henan Cancer Hospital
🇨🇳Zhengzhou, China
Nouvel Hopital Civil - CHU Strasbourg
🇫🇷Strasbourg cedex, France
Universitaetsklinikum Essen
🇩🇪Essen, Germany
Fondazione G Pascale Istituto Nazionale Tumori IRCCS
🇮🇹Napoli, Italy
Ospedale S. Maria Delle Croci
🇮🇹Ravenna, Italy
Gachon University Gil Hospital
🇰🇷Incheon, Korea, Republic of
Seoul National University Bundang Hospital
🇰🇷Seongnam, Korea, Republic of
Narodowy Instytut Onkologii im Marii Sklodowskiej Curie Panstwowy Instytut Badawczy
🇵🇱Warszawa, Poland
Nucleo de Oncologia da Bahia
🇧🇷Salvador, Brazil
Shanghai Pulmonary Hospital
🇨🇳Shanghai, China
Universitaetsklinikum Koeln
🇩🇪Koeln, Germany
National Cancer Center
🇰🇷Goyang-Si, Korea, Republic of
INSTYTUT GENETYKI I IMMUNOLOGII GENIM Sp z o o
🇵🇱Lublin, Poland
Hosp. Univ. Quiron Dexeus
🇪🇸Barcelona, Spain
Hosp Univ Vall D Hebron
🇪🇸Barcelona, Spain
Hosp Univ Fund Jimenez Diaz
🇪🇸Madrid, Spain
Hosp. Univ. 12 de Octubre
🇪🇸Madrid, Spain
Hosp. Clinico Univ. de Valencia
🇪🇸Valencia, Spain
Ankara Bilkent City Hospital
🇹🇷Cankaya, Turkey
Royal Marsden Hospital
🇬🇧Sutton, United Kingdom
Yantai Yuhuangding Hospital
🇨🇳Yantai, China
Institut de cancerologie de l'ouest
🇫🇷Saint-Herblain Cedex, France
Klinikum Chemnitz gGmbH
🇩🇪Chemnitz, Germany
Universitaetsklinikum Muenster
🇩🇪Muenster, Germany
Fondazione IRCCS Istituto Nazionale dei Tumori
🇮🇹Milano, Italy
Istituto Nazionale Tumori Regina Elena
🇮🇹Rome, Italy
National Hospital Organization Nagoya Medical Center
🇯🇵Nagoya-shi, Japan
Severance Hospital Yonsei University Health System
🇰🇷Seoul, Korea, Republic of
Asan Medical Center
🇰🇷Seoul, Korea, Republic of
Hosp. Gral. Univ. de Alicante
🇪🇸Alicante, Spain
Hosp Clinic de Barcelona
🇪🇸Barcelona, Spain
Gazi University Hospital
🇹🇷Ankara, Turkey
Charite Universitaetsmedizin Berlin
🇩🇪Berlin, Germany
Universitaetsklinikum Carl Gustav Carus TU Dresden
🇩🇪Dresden, Germany
Istituto Oncologico Veneto - IRCCS
🇮🇹Padova, Italy
The Cancer Institute Hospital of JFCR
🇯🇵Tokyo, Japan
Chungbuk National University Hospital
🇰🇷Cheongju-si, Korea, Republic of
Chonnam National University Hwasun Hospital
🇰🇷Jeollanam-do, Korea, Republic of
Uniwersyteckie Centrum Kliniczne
🇵🇱Gdansk, Poland
Hosp. Del Mar
🇪🇸Barcelona, Spain
ASST Grande Ospedale Metropolitano Niguarda
🇮🇹Milano, Italy
Seoul National University Hospital
🇰🇷Seoul, Korea, Republic of
Hosp Univ A Coruna
🇪🇸A Coruna, Spain
Hosp. Univ. La Paz
🇪🇸Madrid, Spain
Hosp. Virgen Macarena
🇪🇸Sevilla, Spain
University College London Hospitals Nhs Foundation Trust
🇬🇧London, United Kingdom
Imperial College London and Imperial College Healthcare NHS Trust
🇬🇧London, United Kingdom
Sir Bobby Robson Cancer Trials Research Centre
🇬🇧Newcastle upon Tyne, United Kingdom